Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - moxifloxacin hydrochloride 0.545%{relative} equivalent to to 0.5% moxifloxacin;   - eye drops, solution - 0.5% w/v - active: moxifloxacin hydrochloride 0.545%{relative} equivalent to to 0.5% moxifloxacin   excipient: boric acid hydrochloric acid purified water sodium chloride sodium hydroxide

Israël - anglais - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israël - anglais - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israël - anglais - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israël - anglais - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Nigéria - anglais - NAFDAC (National Agency for Food and Drugs Administration and Control)

blighia sapida 30%,coco nucifera 50%,xylopia aethiopica 20%

Nigéria - anglais - NAFDAC (National Agency for Food and Drugs Administration and Control)

bridelia ferruginea 50%, khaya ivorensis 30%, cassia tora 10%, colocynthis citrillus 5%, xylopia aethiopica 5%

Nigéria - anglais - NAFDAC (National Agency for Food and Drugs Administration and Control)

casstha filiformis, khaya grandifolia, markhama tomentosa, xylopia aethiopica

Nigéria - anglais - NAFDAC (National Agency for Food and Drugs Administration and Control)

khaya grandifolia, bridelia atriovirides, sphenocen-trum jollyanum, xylopia aethiopica, etc

Nigéria - anglais - NAFDAC (National Agency for Food and Drugs Administration and Control)

securidaca longepedunculata 55%, olax subscorpioidea 30%, anthocleista djalonensis 10%, xylopia aethiopica 5%